Trial Profile
OPEN-LABEL, MULTI-CENTER, PHASE 1b/2a CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF IONTOPHORETIC DEXAMETHASONE PHOSPHATE OPHTHALMIC SOLUTION IN PATIENTS HAVING UNDERGONE CATARACT SURGERY WITH IMPLANTATION OF A POSTERIOR CHAMBER INTRAOCULAR LENS (IOL)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Sep 2022
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Ocular inflammation
- Focus Therapeutic Use
- Sponsors EyeGate Pharma; Kiora Pharmaceuticals
- 05 Dec 2016 According to an EyeGate Pharmaceuticals media release, the data from all stages of this study will form the basis for a randomized, double-masked, placebo controlled trial of iontophoretic EGP-437 in cataract surgery patients (CTP 273163).
- 05 Dec 2016 Results published in the an EyeGate Pharmaceuticals Media Release.
- 29 Nov 2016 Status changed from recruiting to completed.